Index RUT
P/E -
EPS (ttm) -5.45
Insider Own 3.28%
Shs Outstand 101.64M
Perf Week -0.11%
Market Cap 6.83B
Forward P/E -
EPS next Y -3.38
Insider Trans -6.45%
Shs Float 101.15M
Perf Month -5.65%
Income -526.24M
PEG -
EPS next Q -1.14
Inst Own 108.45%
Short Float 13.88%
Perf Quarter -20.28%
Sales 7.53M
P/S 906.50
EPS this Y 18.30%
Inst Trans -1.39%
Short Ratio 7.13
Perf Half Y 85.95%
Book/sh -3.80
P/B -
EPS next Y 24.14%
ROA -57.23%
Short Interest 14.04M
Perf Year 65.91%
Cash/sh 5.88
P/C 11.10
EPS next 5Y 15.00%
ROE -
52W Range 25.98 - 110.25
Perf YTD -21.82%
Dividend Est. -
P/FCF -
EPS past 5Y -22.79%
ROI -154.11%
52W High -40.80%
Beta 0.81
Dividend TTM -
Quick Ratio 6.12
Sales past 5Y 12.30%
Gross Margin -82.78%
52W Low 151.23%
ATR (14) 2.71
Dividend Ex-Date -
Current Ratio 6.12
EPS Y/Y TTM -28.21%
Oper. Margin -6589.71%
RSI (14) 44.90
Volatility 3.17% 3.77%
Employees 423
Debt/Eq -
Sales Y/Y TTM -92.04%
Profit Margin -6988.63%
Recom 1.35
Target Price 95.06
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 4.77%
Payout -
Rel Volume 0.46
Prev Close 64.34
Sales Surprise -78.05%
EPS Surprise -43.97%
Sales Q/Q -14.56%
Earnings May 08 AMC
Avg Volume 1.97M
Price 65.27
SMA20 -4.08%
SMA50 -5.31%
SMA200 25.96%
Trades
Volume 900,199
Change 1.45%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-24-24 Downgrade
UBS
Buy → Neutral
$61 → $92
Jan-05-24 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$60 → $90
Nov-09-23 Initiated
Goldman
Buy
$50
Nov-07-23 Initiated
B. Riley Securities
Buy
$66
Aug-15-23 Initiated
SVB Securities
Outperform
$58
Feb-17-23 Initiated
BofA Securities
Neutral
$49
Dec-23-22 Reiterated
Needham
Buy
$60 → $58
Dec-20-22 Initiated
Truist
Buy
$60
Oct-11-22 Initiated
UBS
Buy
$80
Jan-28-22 Initiated
Goldman
Buy
$74
Dec-22-21 Initiated
Oppenheimer
Outperform
$55
Dec-10-21 Initiated
JP Morgan
Overweight
$58
Oct-07-21 Initiated
Jefferies
Buy
$75
Mar-12-21 Initiated
Wolfe Research
Outperform
$50
Feb-18-21 Initiated
Barclays
Overweight
$28
Jan-20-21 Reiterated
H.C. Wainwright
Buy
$22 → $41
Oct-29-20 Initiated
Goldman
Neutral
$16
Jul-10-20 Initiated
Raymond James
Strong Buy
$39
May-05-20 Initiated
Mizuho
Buy
$31
Apr-09-20 Upgrade
Morgan Stanley
Equal-Weight → Overweight
$25
Show Previous Ratings
May-02-24 04:00PM
May-01-24 10:01AM
Apr-29-24 04:00PM
Apr-26-24 04:44PM
06:00AM
04:00PM
Loading…
Apr-24-24 04:00PM
Apr-10-24 09:27AM
07:30AM
Apr-09-24 07:00PM
Apr-05-24 07:30AM
Apr-02-24 04:00PM
Apr-01-24 04:00PM
Mar-25-24 08:15AM
Mar-20-24 08:30AM
Mar-18-24 08:01PM
08:50AM
Loading…
Mar-17-24 08:50AM
Mar-13-24 02:25PM
Mar-12-24 06:46AM
(Thomson Reuters StreetEvents)
Mar-04-24 04:00PM
Mar-01-24 06:47PM
04:00PM
Feb-29-24 07:30AM
Feb-28-24 10:27AM
(FierceBiotech.com) -9.75%
10:22AM
07:30AM
Feb-27-24 05:10PM
04:42PM
04:17PM
(Associated Press Finance)
04:00PM
Feb-13-24 04:00PM
12:38AM
Loading…
Feb-12-24 12:38AM
Feb-09-24 10:01AM
(Investor's Business Daily)
Feb-08-24 09:10AM
Feb-06-24 04:00PM
Feb-05-24 05:30PM
(The Wall Street Journal)
Jan-29-24 07:30AM
Jan-25-24 07:30AM
Jan-18-24 01:00PM
Jan-12-24 04:40PM
02:47PM
01:07PM
05:27AM
Jan-11-24 04:22PM
04:05PM
12:58PM
(The Wall Street Journal)
12:54PM
12:47PM
(The Wall Street Journal)
12:30PM
Jan-10-24 01:04PM
Jan-09-24 01:17PM
Jan-08-24 05:14PM
(The Wall Street Journal) +15.29%
04:42PM
(Investor's Business Daily)
02:12PM
(Investor's Business Daily)
01:11PM
(The Wall Street Journal)
01:05PM
Jan-03-24 04:00PM
06:45AM
Jan-02-24 04:00PM
Dec-29-23 01:01PM
Dec-28-23 03:09PM
(Investor's Business Daily)
02:43PM
09:44AM
Dec-27-23 05:26PM
(Yahoo Finance Video) +82.54%
03:52PM
01:59PM
01:00PM
12:21PM
(Associated Press Finance)
09:41AM
08:34AM
07:39AM
07:32AM
07:30AM
Dec-26-23 04:00PM
Dec-15-23 10:22AM
Dec-07-23 07:30AM
Dec-01-23 04:00PM
Nov-29-23 04:00PM
Nov-10-23 03:04PM
Nov-04-23 12:16PM
Nov-03-23 04:00PM
11:43AM
(Thomson Reuters StreetEvents)
11:20AM
Nov-02-23 06:59PM
05:25PM
04:24PM
(Associated Press Finance)
04:00PM
09:55AM
Nov-01-23 04:00PM
Oct-31-23 02:24PM
12:43PM
Oct-26-23 09:08PM
Oct-23-23 04:00PM
Oct-19-23 07:30AM
Oct-09-23 07:53AM
Oct-06-23 12:45PM
Oct-05-23 04:00PM
Oct-03-23 04:00PM
Oct-02-23 04:00PM
Sep-28-23 07:30AM
Sep-15-23 01:05AM
Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
HENDERSON JOHN T Director Apr 25 '24 Sale 64.54 10,562 681,671 32,070 Apr 25 06:54 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Option Exercise 6.67 28,605 190,795 171,172 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Apr 09 '24 Sale 74.31 32,605 2,422,918 138,567 Apr 09 04:38 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Option Exercise 6.67 28,604 190,789 167,577 Mar 05 04:05 PM Malik Fady Ibraham EVP Research & Development Mar 05 '24 Sale 67.56 32,604 2,202,606 138,973 Mar 05 04:05 PM HENDERSON JOHN T Director Feb 14 '24 Option Exercise 4.44 5,000 22,200 47,632 Feb 14 04:04 PM HENDERSON JOHN T Director Feb 14 '24 Sale 76.48 5,000 382,400 42,632 Feb 14 04:04 PM Blum Robert I President & CEO Feb 13 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 13 04:01 PM Blum Robert I President & CEO Feb 13 '24 Sale 76.85 12,500 960,625 441,797 Feb 13 04:01 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Option Exercise 6.67 28,605 190,795 175,578 Feb 06 04:43 PM Malik Fady Ibraham EVP Research & Development Feb 06 '24 Sale 79.30 32,605 2,585,496 142,973 Feb 06 04:43 PM Blum Robert I President & CEO Jan 31 '24 Option Exercise 6.67 12,500 83,375 454,297 Feb 02 04:41 PM Blum Robert I President & CEO Jan 31 '24 Sale 79.57 12,500 994,625 441,797 Feb 02 04:41 PM Blum Robert I President & CEO Jan 19 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 22 05:19 PM Blum Robert I President & CEO Jan 19 '24 Sale 81.42 12,500 1,017,750 441,797 Jan 22 05:19 PM HENDERSON JOHN T Director Jan 12 '24 Option Exercise 4.44 5,000 22,200 47,632 Jan 12 05:20 PM HENDERSON JOHN T Director Jan 12 '24 Sale 85.14 5,000 425,700 42,632 Jan 12 05:20 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Option Exercise 7.96 11,678 92,957 162,651 Jan 04 04:36 PM Malik Fady Ibraham EVP Research & Development Jan 04 '24 Sale 86.98 15,678 1,363,712 146,973 Jan 04 04:36 PM Blum Robert I President & CEO Jan 02 '24 Option Exercise 6.67 12,500 83,375 454,297 Jan 02 05:55 PM Blum Robert I President & CEO Jan 02 '24 Sale 85.08 12,500 1,063,500 441,797 Jan 02 05:55 PM WIERENGA WENDALL Director Dec 27 '23 Option Exercise 4.44 10,000 44,400 23,653 Dec 27 04:11 PM WIERENGA WENDALL Director Dec 27 '23 Sale 73.60 10,000 736,000 18,653 Dec 27 04:11 PM HENDERSON JOHN T Director Dec 18 '23 Option Exercise 6.72 13,020 87,494 44,838 Dec 19 04:12 PM Blum Robert I President & CEO Dec 18 '23 Option Exercise 6.67 12,500 83,375 454,297 Dec 19 04:13 PM Blum Robert I President & CEO Dec 18 '23 Sale 36.95 12,500 461,875 441,797 Dec 19 04:13 PM HENDERSON JOHN T Director Dec 18 '23 Sale 36.34 2,458 89,324 42,380 Dec 19 04:12 PM Blum Robert I President & CEO Nov 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Dec 01 04:15 PM Blum Robert I President & CEO Nov 30 '23 Sale 32.99 12,500 412,375 441,417 Dec 01 04:15 PM Blum Robert I President & CEO Nov 15 '23 Option Exercise 6.67 12,500 83,375 453,917 Nov 15 05:22 PM Blum Robert I President & CEO Nov 15 '23 Sale 34.57 12,500 432,125 441,417 Nov 15 05:22 PM Malik Fady Ibraham EVP Research & Development Nov 09 '23 Sale 35.40 2,500 88,500 150,664 Nov 09 04:35 PM Blum Robert I President & CEO Oct 30 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 30 04:02 PM Blum Robert I President & CEO Oct 30 '23 Sale 32.17 12,500 402,125 441,417 Oct 30 04:02 PM Blum Robert I President & CEO Oct 16 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 16 05:57 PM Blum Robert I President & CEO Oct 16 '23 Sale 33.70 12,500 421,250 441,417 Oct 16 05:57 PM Malik Fady Ibraham EVP Research & Development Oct 12 '23 Sale 35.89 2,500 89,725 153,164 Oct 12 06:39 PM Blum Robert I President & CEO Oct 06 '23 Option Exercise 6.67 12,500 83,375 453,917 Oct 06 04:52 PM Blum Robert I President & CEO Oct 06 '23 Sale 30.00 12,500 375,000 441,417 Oct 06 04:52 PM Malik Fady Ibraham EVP Research & Development Sep 14 '23 Sale 34.86 2,500 87,150 155,664 Sep 14 04:09 PM Blum Robert I President & CEO Sep 13 '23 Option Exercise 6.67 12,500 83,375 453,917 Sep 13 04:09 PM Blum Robert I President & CEO Sep 13 '23 Sale 34.90 12,500 436,206 441,417 Sep 13 04:09 PM Blum Robert I President & CEO Aug 25 '23 Option Exercise 7.70 12,500 96,275 453,917 Aug 28 06:45 PM Blum Robert I President & CEO Aug 25 '23 Sale 33.99 12,500 424,875 441,417 Aug 28 06:45 PM WIERENGA WENDALL Director Aug 21 '23 Option Exercise 6.72 6,020 40,454 24,225 Aug 21 04:01 PM WIERENGA WENDALL Director Aug 21 '23 Sale 32.02 6,020 192,760 18,205 Aug 21 04:01 PM Blum Robert I President & CEO Aug 11 '23 Option Exercise 9.54 12,500 119,287 453,125 Aug 11 04:18 PM Blum Robert I President & CEO Aug 11 '23 Sale 32.37 12,500 404,589 441,417 Aug 11 04:18 PM Malik Fady Ibraham EVP Research & Development Aug 10 '23 Sale 31.70 2,500 79,250 158,164 Aug 10 04:14 PM Blum Robert I President & CEO Aug 01 '23 Option Exercise 9.65 12,500 120,625 452,108 Aug 01 04:57 PM Blum Robert I President & CEO Aug 01 '23 Sale 32.63 12,500 407,856 441,417 Aug 01 04:57 PM Blum Robert I President & CEO Jul 13 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 13 04:10 PM Blum Robert I President & CEO Jul 13 '23 Sale 35.28 12,500 440,940 441,417 Jul 13 04:10 PM Malik Fady Ibraham EVP Research & Development Jul 13 '23 Sale 35.37 2,500 88,425 160,664 Jul 13 04:09 PM Bhanji Muna Director Jul 07 '23 Sale 34.12 2,000 68,235 14,031 Jul 07 04:17 PM Blum Robert I President & CEO Jul 03 '23 Option Exercise 9.65 12,500 120,625 453,917 Jul 05 04:18 PM Blum Robert I President & CEO Jul 03 '23 Sale 32.60 12,500 407,500 441,417 Jul 05 04:18 PM Blum Robert I President & CEO Jun 12 '23 Option Exercise 9.65 12,500 120,625 453,917 Jun 12 05:49 PM Blum Robert I President & CEO Jun 12 '23 Sale 37.06 12,500 463,250 441,417 Jun 12 05:49 PM Malik Fady Ibraham EVP Research & Development Jun 08 '23 Sale 38.07 2,500 95,175 163,164 Jun 08 04:31 PM Blum Robert I President & CEO May 31 '23 Option Exercise 9.65 12,500 120,625 453,558 Jun 01 05:06 PM Blum Robert I President & CEO May 31 '23 Sale 37.67 12,500 470,875 441,058 Jun 01 05:06 PM Blum Robert I President & CEO May 16 '23 Option Exercise 9.65 12,500 120,625 453,558 May 16 04:33 PM Blum Robert I President & CEO May 16 '23 Sale 37.41 12,500 467,625 441,058 May 16 04:33 PM HENDERSON JOHN T Director May 15 '23 Option Exercise 6.78 4,166 28,245 29,586 May 15 04:07 PM HENDERSON JOHN T Director May 15 '23 Sale 37.77 4,166 157,350 25,420 May 15 04:07 PM Malik Fady Ibraham EVP Research & Development May 11 '23 Sale 39.50 1,787 70,586 165,396 May 11 05:26 PM
Index RUT
P/E -
EPS (ttm) -3.70
Insider Own 7.45%
Shs Outstand 77.93M
Perf Week 12.06%
Market Cap 3.68B
Forward P/E -
EPS next Y -3.54
Insider Trans -6.99%
Shs Float 72.12M
Perf Month 1.18%
Income -214.53M
PEG -
EPS next Q -0.81
Inst Own 90.23%
Short Float 7.24%
Perf Quarter 27.29%
Sales 0.00M
P/S -
EPS this Y 13.21%
Inst Trans 1.41%
Short Ratio 6.44
Perf Half Y 59.73%
Book/sh 7.91
P/B 5.97
EPS next Y -10.42%
ROA -43.45%
Short Interest 5.22M
Perf Year 118.82%
Cash/sh 7.17
P/C 6.59
EPS next 5Y -
ROE -50.16%
52W Range 15.76 - 49.58
Perf YTD 32.66%
Dividend Est. -
P/FCF -
EPS past 5Y -10.59%
ROI -36.57%
52W High -4.80%
Beta 0.65
Dividend TTM -
Quick Ratio 13.07
Sales past 5Y 64.83%
Gross Margin -105.50%
52W Low 199.49%
ATR (14) 2.18
Dividend Ex-Date -
Current Ratio 13.07
EPS Y/Y TTM -17.50%
Oper. Margin 0.00%
RSI (14) 61.27
Volatility 4.92% 4.69%
Employees 290
Debt/Eq 0.10
Sales Y/Y TTM -100.00%
Profit Margin -
Recom 1.21
Target Price 57.14
Option/Short Yes / Yes
LT Debt/Eq 0.09
EPS Q/Q -7.10%
Payout -
Rel Volume 0.84
Prev Close 46.78
Sales Surprise -100.00%
EPS Surprise -4.35%
Sales Q/Q -100.00%
Earnings May 09 AMC
Avg Volume 811.42K
Price 47.20
SMA20 5.88%
SMA50 8.70%
SMA200 45.64%
Trades
Volume 678,175
Change 0.90%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-06-24 Initiated
Citigroup
Buy
$68
Jan-16-24 Initiated
Morgan Stanley
Overweight
$50
Dec-21-23 Initiated
Jefferies
Hold
$35
Nov-20-23 Resumed
JP Morgan
Overweight
$35
Oct-24-23 Resumed
Cantor Fitzgerald
Overweight
$52 → $50
Aug-31-23 Initiated
Oppenheimer
Outperform
$40
Apr-24-23 Initiated
Piper Sandler
Overweight
$56
Mar-30-23 Initiated
Robert W. Baird
Outperform
$48
Nov-30-21 Initiated
JMP Securities
Mkt Outperform
$43
Nov-23-21 Initiated
Evercore ISI
Outperform
$68
Jun-18-21 Upgrade
JP Morgan
Neutral → Overweight
$28
Dec-23-19 Initiated
ROTH Capital
Buy
$37
Feb-14-19 Initiated
H.C. Wainwright
Buy
$35
Aug-13-18 Initiated
Piper Jaffray
Overweight
$40
Aug-13-18 Initiated
Leerink Partners
Outperform
$43
Aug-13-18 Initiated
JP Morgan
Neutral
$29
Show Previous Ratings
May-02-24 04:05PM
Apr-11-24 04:05PM
Mar-28-24 08:10AM
Mar-26-24 07:01PM
Mar-22-24 07:02PM
07:02PM
Loading…
07:02PM
Mar-21-24 02:32AM
Mar-20-24 11:46AM
05:14AM
Mar-19-24 04:48PM
04:03PM
(Investor's Business Daily)
08:08AM
(Investor's Business Daily)
06:16AM
06:08AM
06:00AM
04:05PM
Loading…
Mar-12-24 04:05PM
Mar-11-24 04:05PM
Mar-01-24 08:57AM
Feb-28-24 04:36PM
04:05PM
08:00AM
Feb-15-24 03:14AM
Feb-14-24 04:05PM
Feb-12-24 04:05PM
Jan-26-24 11:01PM
Jan-13-24 05:03AM
Jan-10-24 04:33PM
Jan-05-24 03:03AM
Jan-03-24 08:00AM
Dec-29-23 07:02AM
05:01AM
Loading…
Dec-23-23 05:01AM
Dec-18-23 04:05PM
Dec-11-23 04:05PM
Dec-03-23 05:25AM
Nov-20-23 04:05PM
Nov-17-23 08:39AM
Nov-10-23 05:00PM
Nov-09-23 05:45AM
Nov-08-23 09:55AM
08:50AM
Nov-07-23 04:05PM
Nov-04-23 05:03AM
Oct-23-23 09:55AM
08:50AM
Oct-20-23 01:02AM
Oct-11-23 09:00AM
Oct-10-23 05:00PM
Oct-03-23 07:00AM
Sep-28-23 11:18AM
Sep-20-23 08:00AM
Sep-15-23 08:37AM
Sep-12-23 10:26PM
Sep-11-23 04:04PM
(Investor's Business Daily) +63.31%
04:01PM
12:57PM
06:00AM
05:43AM
Sep-10-23 10:00AM
Sep-05-23 08:55PM
Aug-13-23 09:02AM
Aug-10-23 05:34PM
Aug-08-23 07:00AM
Jul-31-23 08:01AM
Jul-10-23 04:18PM
Jun-21-23 07:59AM
Jun-12-23 07:30AM
Jun-09-23 07:30AM
May-10-23 04:21PM
May-06-23 08:07AM
May-04-23 07:35PM
04:05PM
10:00AM
Apr-16-23 09:34AM
Apr-10-23 04:31PM
Mar-28-23 03:57PM
Mar-10-23 04:37PM
Mar-06-23 07:05AM
Feb-28-23 05:25PM
04:05PM
Feb-10-23 05:21PM
08:01AM
Jan-10-23 04:48PM
Jan-09-23 08:01AM
Dec-12-22 04:01PM
Nov-28-22 08:00AM
Nov-22-22 08:00AM
Nov-14-22 09:15AM
08:00AM
Nov-10-22 04:30PM
Nov-06-22 07:26AM
Oct-13-22 08:00AM
Oct-10-22 04:57PM
Oct-06-22 08:00AM
Oct-03-22 08:00AM
Sep-26-22 10:29AM
Sep-12-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Sep-02-22 08:00AM
Aug-12-22 09:15AM
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Pizzuti Dana Chief Med and Dev Officer Apr 15 '24 Option Exercise 16.89 14,375 242,794 42,161 Apr 17 04:36 PM Struthers Richard Scott President & CEO Apr 15 '24 Option Exercise 1.91 20,000 38,200 257,835 Apr 17 04:30 PM Pizzuti Dana Chief Med and Dev Officer Apr 15 '24 Sale 44.47 14,375 639,256 27,786 Apr 17 04:36 PM Struthers Richard Scott President & CEO Apr 04 '24 Option Exercise 9.28 40,951 380,025 278,786 Apr 08 05:09 PM Struthers Richard Scott President & CEO Apr 04 '24 Sale 49.17 40,951 2,013,561 237,835 Apr 08 05:09 PM Okey Stephanie Director Mar 28 '24 Option Exercise 18.29 17,500 320,075 23,500 Apr 02 04:35 PM Okey Stephanie Director Mar 28 '24 Sale 46.38 17,500 811,650 6,000 Apr 02 04:35 PM Knight Jeff E. Chief Operating Officer Mar 22 '24 Option Exercise 23.98 30,000 719,400 84,939 Mar 26 04:30 PM Knight Jeff E. Chief Operating Officer Mar 22 '24 Sale 44.31 32,359 1,433,675 52,580 Mar 26 04:30 PM Fust Matthew K Director Mar 20 '24 Option Exercise 20.92 60,000 1,254,975 36,036 Mar 22 04:31 PM Pizzuti Dana Chief Med and Dev Officer Mar 20 '24 Option Exercise 16.89 14,375 242,794 38,500 Mar 22 04:52 PM Fust Matthew K Director Mar 20 '24 Sale 44.14 60,000 2,648,150 18,536 Mar 22 04:31 PM Pizzuti Dana Chief Med and Dev Officer Mar 20 '24 Sale 44.06 15,089 664,763 27,786 Mar 22 04:52 PM Wilson Marc CFO Mar 19 '24 Sale 42.91 6,942 297,881 110,630 Mar 20 06:32 PM Betz Stephen F. Chief Scientific Officer Jan 25 '24 Sale 37.26 3,000 111,780 73,298 Jan 26 05:50 PM Betz Stephen F. Chief Scientific Officer Jan 10 '24 Sale 37.65 3,000 112,950 76,298 Jan 12 04:12 PM Pizzuti Dana Chief Med and Dev Officer Jan 03 '24 Option Exercise 16.89 14,375 242,794 20,286 Jan 04 04:45 PM Pizzuti Dana Chief Med and Dev Officer Jan 03 '24 Sale 35.00 14,375 503,125 5,911 Jan 04 04:45 PM Wilson Marc CFO Jan 02 '24 Option Exercise 9.28 10,000 92,800 106,055 Jan 04 04:43 PM Wilson Marc CFO Jan 02 '24 Sale 35.47 10,000 354,700 96,055 Jan 04 04:43 PM Betz Stephen F. Chief Scientific Officer Dec 26 '23 Sale 35.89 3,000 107,670 79,298 Dec 27 05:20 PM Pizzuti Dana Chief Med and Dev Officer Dec 21 '23 Option Exercise 16.89 9,583 161,857 15,494 Dec 22 06:45 PM Pizzuti Dana Chief Med and Dev Officer Dec 21 '23 Sale 34.57 9,583 331,284 5,911 Dec 22 06:45 PM Betz Stephen F. Chief Scientific Officer Dec 11 '23 Sale 32.87 3,000 98,610 82,298 Dec 13 04:44 PM Betz Stephen F. Chief Scientific Officer Nov 27 '23 Sale 31.84 3,000 95,520 85,298 Nov 29 04:31 PM Struthers Richard Scott President & CEO Nov 09 '23 Option Exercise 1.91 50,000 95,500 185,522 Nov 13 04:33 PM Struthers Richard Scott President & CEO Nov 03 '23 Option Exercise 9.28 199,082 1,847,481 334,604 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 03 '23 Sale 30.56 199,082 6,083,946 135,522 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 02 '23 Option Exercise 9.28 918 8,519 136,440 Nov 06 06:02 PM Struthers Richard Scott President & CEO Nov 02 '23 Sale 29.95 918 27,494 135,522 Nov 06 06:02 PM Wilson Marc CFO Nov 01 '23 Option Exercise 9.28 10,000 92,800 105,601 Nov 03 07:38 PM Wilson Marc CFO Nov 01 '23 Sale 28.75 10,000 287,500 95,601 Nov 03 07:38 PM Krasner Alan Seth Chief Medical Officer Oct 17 '23 Option Exercise 12.01 7,000 84,070 50,210 Oct 19 05:01 PM Krasner Alan Seth Chief Medical Officer Oct 17 '23 Sale 30.00 7,000 210,000 43,210 Oct 19 05:01 PM Struthers Richard Scott President & CEO Aug 14 '23 Option Exercise 1.91 10,000 19,100 135,522 Aug 16 04:30 PM Struthers Richard Scott President & CEO Jul 13 '23 Sale 20.35 14,157 288,095 630,805 Jul 13 04:56 PM Struthers Richard Scott President & CEO Jul 12 '23 Sale 20.17 11,459 231,128 644,962 Jul 13 04:56 PM Struthers Richard Scott President & CEO Jul 11 '23 Sale 20.14 24,384 491,094 656,421 Jul 13 04:56 PM Wilson Marc CFO Jun 20 '23 Option Exercise 9.28 20,000 185,600 115,158 Jun 21 05:32 PM Wilson Marc CFO Jun 20 '23 Sale 19.97 30,922 617,403 95,158 Jun 21 05:32 PM Struthers Richard Scott President & CEO Jun 16 '23 Sale 20.81 50,000 1,040,500 680,805 Jun 21 05:27 PM Vivaldi Coelho Rogerio Director Jun 08 '23 Buy 22.06 5,000 110,300 5,000 Jun 09 08:00 AM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite